N@N

Exelixis Announces Webcasts of Investor Events in November and December

^{Published on 2010-11-10 08:41:11 - Market Wire}
 

SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (Nasdaq:EXEL) announced today the following upcoming investor events:

• Lazard Capital Markets Healthcare Conference: Michael M. Morrissey, PhD, the companya™s president and chief executive officer will present at the Lazard Capital Markets Healthcare Conference in New York at 11:25 a.m. EST / 8:25 a.m. PST on Tuesday, November 16, 2010. He will discuss the companya™s development pipeline and provide a general business update.
• EORTC-NCI-AACR Symposium: A conference call to review the data from the six posters presented at the EORTC-NCI-AACR Symposium on the companya™s randomized discontinuation trial of XL184 will be held on Thursday, November 18 at 7:30 a.m. EST / 4:30 a.m. PST. During the conference call, Exelixis management will provide an overview of the data presented at the meeting, and Dr. Matthew Smith of Massachusetts General Hospital will provide an update on the castration-resistant prostate cancer cohort. An audio replay will be available until 11:59 p.m ET/ 8:59 p.m. PT on December 4, 2010. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international), and the passcode is 94605525.
• Piper Jaffray 22^nd Annual aUnpluggeda Health Care Conference: Dr. Morrissey will present at Piper Jaffraya™s 22^nd Annual aUnpluggeda Health Care Conference in New York at 8:00 a.m. EST / 5:00 a.m. PST on Tuesday, November 30, 2010. He will discuss the XL184 data presented at the EORTC-NCI-AACR Symposium and the companya™s development pipeline, and will provide a general business update.
• Exelixis Annual R&D Day: The company will host its Annual R&D Day on Thursday, December 2, 2010 from 10:00 a.m. EST / 7:00 a.m. PST until 2:30 p.m. EST / 11:30 a.m. PST. During this event, key clinical investigators for the companya™s randomized discontinuation trial of XL184 will discuss the data presented at the EORTC-NCI-AACR Symposium. In addition, Exelixis management will outline the development priorities for XL184, discuss the companya™s development and corporate strategy, and provide a general business update.

Each of these investor events will be webcast and may be accessed on the Event Calendar page under Investors at [ http://www.exelixis.com ] for a period of 30 days following the date of the event.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer. Currently, Exelixisa™ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the companya™s web site at [ www.exelixis.com ].